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Background: Ruminant species are at risk of developing abomasal ulceration, but there
is a lack of pharmacokinetic data for anti-ulcer therapies, such as the proton pump
inhibitor pantoprazole, in goats.
Objective: The primary study objective was to estimate the plasma pharmacokinetic
parameters for pantoprazole in adult goats after intravenous administration. A secondary
objective was to describe the pharmacokinetic parameters for the metabolite,
pantoprazole sulfone, in goats.
Methods: Pantoprazole was administered intravenously to six adult goats at a dose
of 1 mg/kg. Plasma samples were collected over 36h and analyzed via reverse
phase high performance liquid chromatography for determination of pantoprazole and
pantoprazole sulfone concentrations. Pharmacokinetic parameters were determined by
non-compartmental analysis.
Results: Plasma clearance, elimination half-life, and volume of distribution of
pantoprazole were estimated at 0.345 mL/kg/min, 0.7 h, and 0.9 L/kg, respectively
following IV administration. The maximum concentration, elimination half-life and area
under the curve of pantoprazole sulfone were estimated at 0.1 µg/mL, 0.8 h, and 0.2
hr∗ µg/mL, respectively. The global extraction ratio was estimated 0.00795 ± 0.00138.
All animals had normal physical examinations after conclusion of the study.
Conclusion: The reported plasma clearance for pantoprazole is lower than reported
for foals, calves, and alpacas. The elimination half-life appears to be < that reported for
foals and calves. Future pharmacodynamic studies are necessary for determination of
the efficacy of pantoprazole on acid suppression in goats.
Keywords: goat (capra aegagrus hircus), pantoprazole, pantoprazole sulfone, pharmacokinetics, ulcer
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INTRODUCTION

University of Tennessee. During the study they were fed a diet
of ad libitum grass hay. None of the animals had been medicated
within the 4 weeks prior to the study and all were current on
vaccination for Clostridium perfringens types C and D, as well as
tetanus. Before employment for the study all goats were deemed
healthy based on physical examination by large animal veterinary
specialist. All goats had an intravenous catheter aseptically placed
into each jugular vein as previously reported, with one catheter
designated for blood collection and another one utilized for drug
administration (11, 19). Pantoprazole was reconstituted to a 4
mg/mL concentration per label instruction. A 1 mg/kg dosage
of pantoprazole (Pantoprazole sodium for injection, AuroMedics
Pharma LLC, East Windsor, NJ) was administered intravenously
to each goat. Blood samples were collected at 0, 10, 20, 30, and
45 min after collection as well as 1, 1.5, 2, 3, 4, 8, 12, 18, 24, and
36 h after drug administration. Blood samples were placed into
a lithium heparin tubes after collection, and then immediately
spun down and transferred to cryogenic vials placed into storage
at −80◦ C until analysis.

Pantoprazole is a member of the proton pump inhibitor (PPI)
class of gastro protectant drugs that functions by irreversibly
binding to the hydrogen-potassium-ATPase pump in gastric
parietal cells, resulting in reduced gastric acid secretion and
increased gastric pH (1, 2). In veterinary species, the PPIs
have been recognized as the most potent suppressors of gastric
acid (3). Drugs of the PPI class such as omeprazole have been
thoroughly investigated as a treatment for gastric ulceration in
horses (4). Abomasal ulceration is the manifestation of gastric
ulceration in ruminant species (5), which can be caused by
disease, stress, or as an adverse effect of some medications, such
as nonsteroidal anti-inflammatory drugs. Reports in the literature
of pharmacologic options for the management of this disease in
ruminant species is currently limited.
Abomasal ulcerations range in severity from non-perforating
to perforating with diffuse peritonitis in ruminant species (5).
Multiple therapies have been described for ulceration in other
veterinary species, including coating agents, sucralfate, histamine
type two receptor antagonists, as well as PPIs (3). One of the
challenges with gastro protectant therapy in mature ruminants
is the rumen’s ability to dilute and degrade orally administered
medications. As such, parenteral administration provides a route
of bypassing the barriers posed by the rumen for oral therapies.
Famotidine has been described for use in mature steers, but
it requires multiple daily administrations and had diminishing
effects over time (6). Omeprazole has been described in some
mature psuedoruminant species, such as llamas (7, 8) but the
injectable formulation is not available globally, and other routes
of administration, such as oral and rectal appear to lead to poor
absorption (8, 9). Pantoprazole is commonly used in human
medicine, is readily available, and as such may be a useful therapy
for goats at risk for ulceration.
The use of pantoprazole has been describe in multiple
ruminant species including cattle, alpacas, sheep, goats, yaks, and
camels (10–17). Most of these uses are focused on increasing
the abomasal luminal pH to create an environment conducive
to the healing of gastric ulcers. Among large animal species,
the pharmacokinetics of pantoprazole has only been reported
in alpacas, neonatal calves, and foals (10, 11, 18). The primary
objective of this study was to determine the pharmacokinetics
of pantoprazole in adult goats after single intravenous (IV)
administration. A secondary objective of this study was to
evaluate the pharmacokinetics of the metabolite pantoprazole
sulfone, after IV administration of pantoprazole in adult goats.

Analytical Method
Analysis of pantoprazole in plasma samples was conducted using
reverse phase high performance liquid chromatography method.
The system consisted of a computer equipped with Empower
software (Waters), a 2,695 separations module, and a 2,487
UV absorbance detector. The compounds were separated on
a Symmetry C18 (4.6 x 150 mm, 5µm) column with a 5µm
Symmetry C18 guard column. The mobile phase was a mixture
of 0.1 M sodium phosphate dibasic (14.2857 g Na2 HPO4 ) and
acetonitrile (68:32). The flow rate was 1 mL/min and absorbance
was measured at 290nm.
Pantoprazole and the metabolite were extracted from plasma
samples using a liquid-liquid extraction method. Samples that
were previously frozen were thawed, vortex-mixed, and 100µl
of plasma was transferred to a 13 x 100mm screw top tube
followed by 10µl of tinidazole (internal standard, 100 µg/mL)
and 2 mL chloroform. The tubes were rocked for 15 min and
then centrifuged for 20 min at 1,000 x g. The organic layer
was transferred to a clean tube and evaporated to dryness with
nitrogen gas. Samples were reconstituted in 250µL of mobile
phase and 100µL was analyzed.
Standard curves for the plasma analysis were prepared by
fortifying untreated, pooled plasma with pantoprazole and its
metabolite, which produced a linear concentration range of
0.01–100 µg/mL. Methanol was used as a solvent. Calibration
samples were prepared the same as the plasma samples. Average
recovery for pantoprazole and its metabolite was 100 and 90%,
respectively. The average recovery for the internal standard was
99%. The QC samples used for validation were 0.03, 0.3, 3, and
30 µg/mL and the intra and inter-assay variability ranged from 2
to 11 % for pantoprazole and 3– 9% for the metabolite. The lower
limit of quantification for both was 0.1 µg/mL.

MATERIALS AND METHODS
The study protocol was reviewed and approved by the
Institutional Animal Care and Use Committee of the University
of Tennessee (Protocol # 2825-0221). Six healthy adult goats were
utilized for this study. Three goats were pygmies and three were
pygmy-crosses. Ages were 3.2 ± 0.7 years and weights were
42.1 ± 6.1 kgs. Four of the goats were intact females, and two
were castrated males. Goats were sourced from the teaching
herd of the Veterinary Research and Education Center of the
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Pharmacokinetic parameters for pantoprazole systemic
disposition were determined from plasma time vs. concentration
data as previously described by Olivarez et al. (11).
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Pharmacokinetic analysis was performed via commercial
modeling software using a statistical moments approach
(PKanalix, Monolix Suite 2020R1, Lixoft, France). Standard time
vs. concentration data for pantoprazole were determined via
reverse phase high performance liquid chromatography from
the blood collected at 15 time points ranging from 0 to 36 h
after administration.
Standard PK parameters were generated for individual goats,
as follows:

concentration; area under the curve (at last measurement
and extrapolated to infinity); area under the moments curve;
elimination half-life; and mean residence time. Pharmacokinetic
modeling was performed via commercial modeling software
(PKanalix, Monolix Suite 2020R1, Lixoft, France). Standard time
vs concentration data for pantoprazole sulfone were determined
via reverse phase high performance liquid chromatography from
the blood collected at 15 time points ranging from 0 to 36h
after administration.

1. Maximum concentration extrapolated to time zero,
C0 (pantoprazole);
2. Area under pantoprazole concentration–time curve, AUClast
and AUCinf;
3. Area under the moment curve, AUMCinf;
4. Pantoprazole
mean
residence
time,
MRT
= AUMCinf/AUCinf;
5. Pantoprazole terminal half-life, T1/2 (λz)) = ln (2)/λz;
6. Pantoprazole systemic clearance, CL = Dose/AUCinf;
7. Volume of distribution of pantoprazole at steady-state, Vss =
CL × MRT

RESULTS
No adverse effects were observed in any of the goats used for this
study. No animal displayed altered appetite or attitude, and no
edema or signs of anaphylaxis were observed. No concentrations
of pantoprazole were detected after 4h in any animal. Table 1

For data analysis, a log trapezoidal rule was used to estimate the
area under the pantoprazole time-curves. Summary statistics on
the individual PK parameters were performed thereafter to derive
the geometric mean, median and (min–max) range.
Global extraction ratio (Ebody) was first calculated as reported
by Toutain and Bousquet-Melou (20), with:
Ebody = Systemic clearance/Cardiac output
First calculated for each individual goat, and then combined for a
mean value. With the goat cardiac output calculated as previously
reported (20, 21) as follows:
Cardiac output = 180 × BW(kg)−0.19
Pharmacokinetic parameters for the metabolite, pantoprazole
sulfone were determined from plasma time vs. concentration
data as previously described for norfentanyl (22). Parameters
described are: maximum concentration; time to maximum

FIGURE 1 | Mean plasma pantoprazole concentration (logarithmic scale) vs.
time (hr) profiles for adult goats (n = 6) following intravenous (IV) single dose
administration of 1.0 mg/kg of pantoprazole. Mean is represented by a black
circle with error bars.

TABLE 1 | Pantoprazole pharmacokinetic parameters following a single intravenous (1 mg/kg) administration to adult goats.
Compound
Pantoprazole

Parameter

Unit

Geomean

Median

Min

Max

C0

µg/mL

3.1

4.1

1.0

5.9

AUClast

hr*µg/mL

1.1

1.1

0.7

1.8

AUCinf

hr*µg/mL

1.1

1.2

0.8

1.8

AUMCinf

hr2 *µg/mL

0.6

0.7

0.3

1.0

MRTINF

hr

0.5

0.5

0.4

0.9

Cl

mL/kg/hr

20.5

20.5

13.3

31.4

T1/2 (λz)

hr

0.7

0.6

0.5

1.5

Vss

L/kg

0.5

0.5

0.3

1.2

Vz

L/kg

0.9

0.8

0.4

2.7

AUClast, Area under pantoprazole concentration–time curve from time zero to last measurement; AUCinf, Area under pantoprazole concentration–time curve from time zero to infinity;
AUMCinf, the area under the first-moment curve from time zero to infinity; MRTinf, Mean residence time extrapolated to infinity; Cl, Plasma clearance; T1/2 (λz), Elimination half-life; C0,
Maximum concentration extrapolated to time zero; Cmax, Maximum concentration; Vz, Volume of distribution (terminal phase); Vss, Volume of distribution at steady-state.
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TABLE 2 | Pantoprazole sulfone pharmacokinetic parameters following a single intravenous (1 mg/kg) administration of pantoprazole sodium to adult goats.
Compound

Parameter

Unit

Pantoprazole

Cmax

µg/mL

Sulfone

Tmax

hr

AUClast

hr*µg/mL

Geomean

Median

Min

Max

0.1

0.2

0.04

0.4

0.5

0.5

0.3

0.8

0.2

0.2

0.1

0.6

AUCinf

hr*µg/mL

0.2

0.2

0.1

0.7

AUMCinf

hr2 *µg/mL

0.3

0.3

0.1

0.9

T1/2 (λz)

hr

0.8

0.9

0.5

1.0

MRTINF

hr

1.3

1.4

1.1

1.6

Cmax, Maximum concentration; Tmax, Time to maximum concentration; AUClast, Area under pantoprazole concentration–time curve from time zero to last measurement; AUCinf, Area
under pantoprazole concentration–time curve from time zero to infinity; AUMCinf, the area under the first-moment curve from time zero to infinity; T1/2 (λz), Elimination half-life; MRTinf,
Mean residence time extrapolated to infinity.

compared to other veterinary species. The elimination half-life
of pantoprazole in the goats in our study was (mean of 0.7 hr)
was < observed in foals (1.4 hr) and calves (2.8 hr), however it
was longer than the observed elimination half-life in alpacas (0.5
hr) (10, 11, 18). Clearance (mean) in our goats (20.5 mL/kg/hr,
approximately 0.341 mL/kg/min) was lower than reported for
foals (1.3 mL/kg/min), calves (4.5 mL/kg/min), or alpacas (12.2
mL/kg/min)(10, 11, 18). This is an interesting finding as the
rapid elimination half-life could be consistent with an increased
relative clearance value. However, half-life is a hybrid parameter,
which is a function of clearance and distribution volume, so it
is possible that interspecies differences in volume of distribution
could contribute to the differences in parameters. In addition
to species-specific differences, it is also possible that analytical
sensitivity could contribute to differences in parameters. The
observed extraction ratio was lower (0.00795) than reported
for calves (0.053). It is possible that these differences could be
due to species-specific variances of pantoprazole metabolism, or
potentially as a factor of age, as the goats in this study were adults,
and the previous studies of foals and calves utilized neonates.
Goats, due to their selective browse grazing behavior are thought
to have more robust enzyme systems for metabolizing xenobiotic
substances than non-specific grazers such as cattle (23), so these
differences compared to calves could also be species-specific.
There is currently a paucity of information regarding the
disposition of the metabolites of pantoprazole in veterinary
species. In calves, pantoprazole sulfone has been detected in
tissues 5 days after administration. In that study, no levels
of the parent drug pantoprazole were detected in tissue at
any time (11). In dogs, two metabolites of pantoprazole
have been detected after intravenous administration,
pantoprazole sulfone and pantoprazole thioether (24). In
humans, pantoprazole sulfone is used in pharmacokinetic
studies, and population variation in pharmacokinetics has
been observed, particularly in obese children (25, 26). In
obese children, a variation of 3–5 times normal parameters
had been observed, and it has been recommended to
avoid empiric dosage escalation in these patients (25).
Pantoprazole is thought to be metabolized in the liver by
CYP2C19 enzymes, with the majority of the drug excreted in
the urine.

FIGURE 2 | Mean plasma pantoprazole sulfone concentration (logarithmic
scale) vs. time (hr) profiles for adult goats (n = 6) following intravenous (IV)
single dose administration of 1.0 mg/kg of pantoprazole. Mean is represented
by a black circle with error bars.

displays the geometric mean, median, minimum and maximum
of the pharmacokinetic parameters of pantoprazole for the goats
in our study. The elimination half-life, Vz and AUC were
(arithmetic mean ± standard deviation) were: 0.7 ± 0.4 (hr); 1.1
± 0.9 (L/kg); and 1.2 ± 0.4 (hr∗ µg/mL), respectively. Figure 1
presents the time vs. concentration curve for pantoprazole. Mean
extraction ratio for pantoprazole was 0.795 ± 0.138 %.
Table 2 displays the geometric mean, median, minimum
and maximum of the pharmacokinetic parameters of the
metabolite pantoprazole sulfone within the goats of our study. No
concentrations of pantoprazole sulfone were detected after 4h in
any animal. Figure 2 presents the time vs. concentration curve
for pantoprazole sulfone.

DISCUSSION
When administered intravenously at 1 mg/kg as a single dose,
pantoprazole is characterized by rapid elimination in goats

Frontiers in Veterinary Science | www.frontiersin.org

4

September 2021 | Volume 8 | Article 744813

Smith et al.

Caprine Pantoprazole Pharmacokinetics

Of specific interest would be the correlation between area
under the curve and clinical efficacy. Currently, the epigenetic
potential of pantoprazole has not been investigated in any
species, and it is unknown if pantoprazole may have any
epigenetic effects or quasi-epigenetic effects such as other
receptor down- or up-regulation (38). Additional studies could
utilize nonlinear mixed effects modeling to evaluate variability
in pantoprazole pharmacokinetics (39). Further studies will
also have to determine the effect of pantoprazole on the
gastrointestinal microbiome resulting from the potential changes
in gastrointestinal pH. Finally, as the use of pantoprazole would
be considered extra-label usage (14), future studies to determine
withdrawal intervals will be necessary in goats.
In conclusion, pantoprazole administered by intravenous
injection appears to be well tolerated and quickly eliminated
in adult goats. Plasma clearance appears to be reduced and
elimination half-life appear to be faster than previous reports in
foals, calves, and alpacas. Pantoprazole sulfone was detectable
in the plasma for up to 4h after administration, although at
lower concentrations than the parent drug. Future studies in
larger study populations are required to completely elucidate the
pharmacokinetics and efficacy of pantoprazole in goats.

In human patients, several adverse effects have been
attributable
to
pantoprazole
including
anaphylaxis,
thrombocytopenia and electrolyte disorders (27–31). While
uncommon, these adverse effects also appear to be limited to
geriatric human patients that undergo long-term therapy with
pantoprazole (31). Pancreatitis and peripheral edema have also
been reported in human patients treated with pantoprazole
(32–34). A case of pantoprazole-induced hyperthermia was
reported in a human patient, however, none of our study
goats had elevated temperatures during the study (35). While
an investigation of adverse effects was beyond the scope of
our present study, no gross adverse effects, such as edema or
anaphylaxis were observed in this population. This is consistent
with a retrospective study investigating the safety of pantoprazole
in hospitalized ruminants (12), as well as several cases reported
in the literature of the use of pantoprazole in goats (13, 14, 36),
although future safety investigations are necessary to completely
capture the safety profile of this drug in caprine patients.
Limitations of this study include its small sample size.
However, many veterinary pharmacokinetic studies employ six
animals, and studies of four–six animals are typically adequate
for describing pharmacokinetics (37). An additional limitation
lies in the rapid nature of the elimination of pantoprazole in
the goat, which combined with the study sampling schedule,
could potentially not allow a thorough characterization of
the elimination phase. Future studies may want to consider
higher dosages or potentially extravascular administration, such
as subcutaneous administration to prolong drug exposure, or
increasing the frequency of early sampling. An additional
limitation is the inability to provide a complete pharmacokinetic
profile for pantoprazole sulfone, as at this time, the complete
metabolism of pantoprazole in the goat is unknown. Due to the
potential genetic nature of CYP2C19 enzyme activity, the small
population of animals could be a limitation, although all of the
study goats were unrelated, and they represented several different
breed crosses. Future studies to investigate the metabolism of
pantoprazole in the goat will be needed to determine the ratios
of and specific metabolites.
This study lays the foundation for multiple lines of work.
Future endeavors will need to investigate the pharmacodynamics
and efficacy of pantoprazole in goats to determine if the observed
increased elimination compared to other species results in
a decreased efficacy of the therapeutic drug. Pantoprazole is
thought to have activity beyond its duration in the system
due to the irreversible nature of its binding at the proton
pump. It is unknown if a specific concentration needs to
be achieved for a specific time period for the desired effect.

DATA AVAILABILITY STATEMENT
The original contributions presented in the study are included
in the article/supplementary material, further inquiries can be
directed to the corresponding author/s.

ETHICS STATEMENT
The animal study was reviewed and approved by Institutional
Animal Care and Use Committee, University of Tennessee.

AUTHOR CONTRIBUTIONS
JS, JM, and SC developed the experimental design. WS-G, RR, BF,
OE, AG, and LH contributed to logistical support, assessment of
animal health, and data collection. LH, SC, and JB developed the
analytical method for determination of concentration. JS and JM
performed the pharmacokinetic analysis. All authors contributed
to manuscript construction.

ACKNOWLEDGMENTS
The authors wish to thank Laura Fischer for her assistance with
sample collection.

REFERENCES

2. Dekel R, Morse C, Fass R. The role of proton pump inhibitors
in gastro-esophageal reflux disease. Drugs. (2004) 64:277–95.
doi: 10.2165/00003495-200464030-00004
3. Marks SL, Kook PH, Papich MG, Tolbert MK, Willard MD. ACVIM
consensus statement: support for rational administration of gastrointestinal
protectants to dogs and cats. J Vet Intern Med. (2018) 32:1823–40.
doi: 10.1111/jvim.15337

1. Cheer SM, Prakash A, Faulds D, Lamb HM. Pantoprazole an update of its pharmacological properties and therapeutic
use in the management of acid-related disorders. Drugs.
(2003)
63:101–32.
doi:
10.2165/00003495-20036301000006

Frontiers in Veterinary Science | www.frontiersin.org

5

September 2021 | Volume 8 | Article 744813

Smith et al.

Caprine Pantoprazole Pharmacokinetics

25. Shakhnovich V, Brian Smith P, Guptill JT, James LP, Collier DN, Wu H,
et al. A population-based pharmacokinetic model approach to pantoprazole
dosing for obese children and adolescents. Paediatr Drugs. (2018) 20:483–95.
doi: 10.1007/s40272-018-0305-1
26. Shakhnovich V, Smith PB, Guptill JT, James LP, Collier DN, Wu H, et al.
Obese children require lower doses of pantoprazole than nonobese peers
to achieve equal systemic drug exposures. J Pediatr. (2018) 193:102–8.
doi: 10.1016/j.jpeds.2017.10.011
27. Gonzalez P, Soriano V, Lopez P, Niveiro E. Anaphylaxis to proton
pump inhibitors. Allergol Immunopathol (Madr). (2002) 30:342–3.
doi: 10.1016/S0301-0546(02)79150-7
28. Miller JL, Gormley AK, Johnson PN. Pantoprazole-induced
thrombocytopenia. Indian J Pediatr. (2009) 76:1278–9. doi: 10.1007/
s12098-009-0224-9
29. Gupta PP, Bhandari R, Mishra DR, Agrawal KK, Jirel S, Malla G. Anaphylactic
reactions due to pantoprazole: case report of two cases. Int Med Case Rep J.
(2018) 11:125–7. doi: 10.2147/IMCRJ.S153099
30. Ferreira F, Mateus S, Santos AR, Moreira H, Ferreira NR. Pantoprazole-related
symptomatic hyponatremia. Eur J Case Rep Intern Med. (2016) 3:000341.
doi: 10.12890/2015_000341
31. Uyar S, Dolu S, Yolcular BO, Ellidag HY, Kok M, Bostan F, et al. Short-term
effect of high-dose pantoprazol on serum and urinary magnesium levels. Clin
Lab. (2018) 64:263–8. doi: 10.7754/Clin.Lab.2017.170822
32. Murtaza G, Khalid MF, Mungo NA. Recurrent pantoprazole-associated
pancreatitis. Am J Ther. (2018) 25:e492–e3. doi: 10.1097/MJT.0000000000
000567
33. Das S, Ganguly A, Ghosh A, Mondal S, Dey JK, Saha I. Oral pantoprazoleinduced acute pancreatitis in an 11-year-old child. Ther Drug Monit. (2012)
34:242–4. doi: 10.1097/FTD.0b013e3182526e6a
34. Brunner G, Athmann C, Boldt JH. Reversible pheripheral edema in female
patients taking proton pump inhibitors for peptic acid diseases. Dig Dis Sci.
(2001) 46:993–6. doi: 10.1023/A:1010745624971
35. Schiller D, Maieron A, Schöfl R, Donnerer J. Drug fever due to a single dose
of pantoprazole. Pharmacology. (2014) 94:78–9. doi: 10.1159/000364781
36. Butty EM, McKinney CA, Prisk AJ. Treatment of a flunixin meglumine
overdose with intravenous administration of lipid emulsion and therapeutic
plasma exchange in a Nigerian dwarf buck kid (capra aegagrus hircus). J Vet
Intern Med. (2021) 35:1626–30. doi: 10.1111/jvim.16124
37. Riviere JE, Chittenden J. Study design and data analysis. In: Riviere JE, editor.
Comparative Pharmacokinetics, 2 ed. Ames, IA: Iowa State University Press
(2011). p. 311. doi: 10.1002/9780470959916.ch14
38. Anderson SJ, Feye KM, Schmidt-McCormack GR, Malovic E, Mlynarczyk GS,
Izbicki P, et al. Off-Target drug effects resulting in altered gene expression
events with epigenetic and “Quasi-Epigenetic” origins. Pharmacol Res. (2016)
107:229–33. doi: 10.1016/j.phrs.2016.03.028
39. Bon C, Toutain PL, Concordet D, Gehring R, Martin-Jimenez T, Smith
J, et al. Mathematical modeling and simulation in animal health. Part
III: using nonlinear mixed-effects to characterize and quantify variability
in drug pharmacokinetics. J Vet Pharmacol Ther. (2018) 41:171–83.
doi: 10.1111/jvp.12473

4. Zavoshti FR, Andrews FM. Therapeutics for equine gastric ulcer
syndrome. Vet Clin North Am Equine Pract. (2017) 33:141–62.
doi: 10.1016/j.cveq.2016.11.004
5. Hund A, Wittek T. Abomasal and third compartment ulcers in ruminants
and south American camelids. Vet Clin North Am Food Anim Pract. (2018)
34:35–54. doi: 10.1016/j.cvfa.2017.10.003
6. Balcomb CC, Heller MC, Chigerwe M, Knych HK, Meyer AM.
Pharmacokinetics and efficacy of intravenous famotidine in adult cattle.
J Vet Intern Med. (2018) 32:1283–9. doi: 10.1111/jvim.15080
7. Christensen JM, Limsakun T, Smith BB, Hollingshead N, Huber M.
Pharmacokinetics and pharmacodynamics of antiulcer agents in llama. J Vet
Pharmacol Ther. (2001) 24:23–33. doi: 10.1046/j.1365-2885.2001.00302.x
8. Poulsen KP, Smith GW, Davis JL, Papich MG. Pharmacokinetics of
oral omeprazole in llamas. J Vet Pharmacol Ther. (2005) 28:539–43.
doi: 10.1111/j.1365-2885.2005.00696.x
9. Marmulak T, Stanley S, Kass PH, Wiebe V, McKemie D, Pusterla N.
Pharmacokinetics of intrarectal omeprazole in alpacas. J Vet Pharmacol Ther.
(2010) 33:371–5. doi: 10.1111/j.1365-2885.2009.01149.x
10. Smith GW, Davis JL, Smith SM, Gerard MP, Campbell NB, Foster DM.
Efficacy and pharmacokinetics of pantoprazole in alpacas. J Vet Intern Med.
(2010) 24:949–55. doi: 10.1111/j.1939-1676.2010.0508.x
11. Olivarez JD, Kreuder AJ, Tatarniuk DM, Wulf LW, Dembek KA, Mochel
JP, et al. Pharmacokinetics and tissue levels of pantoprazole in neonatal
calves after intravenous administration. Front Vet Sci. (2020) 7:580735.
doi: 10.3389/fvets.2020.580735
12. Smith JS, Kosusnik AR, Mochel JP, A retrospective clinical investigation of the
safety and adverse effects of pantoprazole in hospitalized ruminants. Front Vet
Sci. (2020) 7:97. doi: 10.3389/fvets.2020.00097
13. Smith J, Klostermann C, Harm T, Breuer R, Kovalik DA, Bornkamp J, et
al. Abomasal hamartoma in a La Mancha wether. Vet Rec Case Rep. (2017)
5:e000515. doi: 10.1136/vetreccr-2017-000515
14. Poirier NC, Smith JS, Breuer RM, Farrell AM, Klostermann CA, Tseng
CT, et al. Management of hematometra in a boer doe. Clin Theriogenology.
(2020) 12:39–45.
15. Smith JS, Sheley M, Chigerwe M. Aspiration pneumonia in two Tibetan yak
bulls (Bos grunniens) as a complication of ketamine-xylazine-butorphanol
anesthesia for recumbent castration. J Zoo Wildl Med. (2018) 49:242–6.
doi: 10.1638/2016-0205R1.1
16. Rosser JM, Jacob SI, Brounts SH. Use of tube cystostomy in the surgical
management of obstructive urolithiasis in a Bactrian camel. J Am Vet Med
Assoc. (2019) 254:868–73. doi: 10.2460/javma.254.7.868
17. Smith JS, Zhou X, Merkatoris PT, Klostermann CA, Breuer RM. Medical
management of hemorrhagic bowel syndrome in a beef bull. Case Rep Vet
Med. (2019) 2019:1−5. doi: 10.1155/2019/9209705
18. Ryan CA, Sanchez LC, Giguere S, Vickroy T. Pharmacokinetics and
pharmacodynamics of pantoprazole in clinically normal neonatal foals.
Equine Vet J. (2005) 37:336–41. doi: 10.2746/0425164054529427
19. Smith JS, Borts DJ, Slagel CC, Rajewski SM, Bousquet-Melou A, Ferran
AA, et al. Pharmacokinetics of ertapenem in sheep (ovis aries) with
experimentally induced urinary tract infection. Comp Med. (2019). 69:413–8.
doi: 10.30802/AALAS-CM-18-000144
20. Toutain PL, Bousquet-Melou A. Plasma clearance. J Vet Pharmacol Ther.
(2004) 27:415–25. doi: 10.1111/j.1365-2885.2004.00605.x
21. Smith JS, Marmulak TL, Angelos JA, Lin Z, Rowe JD, Carlson JL, et al.
Pharmacokinetic parameters and estimated milk withdrawal intervals for
domestic goats (capra aegagrus hircus) after administration of single and
multiple intravenous and subcutaneous doses of flunixin meglumine. Front
Vet Sci. (2020) 7:213. doi: 10.3389/fvets.2020.00213
22. Smith JS, Coetzee JF, Fisher IWG, Borts DJ, Mochel JP. Pharmacokinetics
of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical
performances on fentanyl parameter estimation. J Vet Pharmacol Ther. (2018)
41:555–61. doi: 10.1111/jvp.12501
23. Toutain PL, Ferran A, Bousquet-Mélou A. Species differences in
pharmacokinetics and pharmacodynamics. Handb Exp Pharmacol. (2010)
199:19–48. doi: 10.1007/978-3-642-10324-7_2
24. Xie Z, Chen X, Jin F, Zhong D. Simultaneous determination of pantoprazole
and its two metabolites in dog plasma by HPLC. J Chromatogr Sci. (2005)
43:271–5. doi: 10.1093/chromsci/43.5.271

Frontiers in Veterinary Science | www.frontiersin.org

Conflict of Interest: The authors declare that the research was conducted in the
absence of any commercial or financial relationships that could be construed as a
potential conflict of interest.
Publisher’s Note: All claims expressed in this article are solely those of the authors
and do not necessarily represent those of their affiliated organizations, or those of
the publisher, the editors and the reviewers. Any product that may be evaluated in
this article, or claim that may be made by its manufacturer, is not guaranteed or
endorsed by the publisher.
Copyright © 2021 Smith, Mochel, Soto-Gonzalez, Rahn, Fayne, Escher, Geletka,
Harvill, Bergman and Cox. This is an open-access article distributed under the
terms of the Creative Commons Attribution License (CC BY). The use, distribution
or reproduction in other forums is permitted, provided the original author(s) and
the copyright owner(s) are credited and that the original publication in this journal
is cited, in accordance with accepted academic practice. No use, distribution or
reproduction is permitted which does not comply with these terms.

6

September 2021 | Volume 8 | Article 744813

